RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 1-1 ◽  
Author(s):  
Mark R. Gilbert ◽  
James Dignam ◽  
Minhee Won ◽  
Deborah T. Blumenthal ◽  
Michael A. Vogelbaum ◽  
...  
Keyword(s):  
Annual Meeting ◽  
Controlled Trial ◽  
Phase Iii ◽  
Newly Diagnosed ◽  
Double Blind ◽  
Daily News ◽  
Double Blind Placebo ◽  
Online Supplement ◽  
Newly Diagnosed Glioblastoma ◽  
Final Text

1 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Sunday, June, 2, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

Results of the X-PECT study: A phase III randomized double-blind placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA3501-LBA3501
Author(s):  
Johanna C. Bendell ◽  
Thomas J. Ervin ◽  
Neil N. Senzer ◽  
Donald A. Richards ◽  
Irfan Firdaus ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Annual Meeting ◽  
Phase Iii ◽  
Controlled Study ◽  
Double Blind ◽  
Daily News ◽  
Double Blind Placebo ◽  
Online Supplement ◽  
Final Text

LBA3501 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA2010-LBA2010 ◽  
Author(s):  
Erik P. Sulman ◽  
Minhee Won ◽  
Deborah T. Blumenthal ◽  
Michael A. Vogelbaum ◽  
Howard Colman ◽  
...  
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
Phase Iii ◽  
Newly Diagnosed ◽  
Predictors Of Outcome ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
Newly Diagnosed Glioblastoma ◽  
Final Text

LBA2010 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Sunday, June, 2, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)—PISCES study, NCT 01064310.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. CRA4502-CRA4502 ◽  
Author(s):  
Bernard J. Escudier ◽  
Camillo Porta ◽  
Petri Bono ◽  
Ugo De Giorgi ◽  
Omi Parikh ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Annual Meeting ◽  
Patient Preference ◽  
Renal Cell ◽  
Double Blind ◽  
Daily News ◽  
Double Blind Placebo ◽  
Online Supplement ◽  
Final Text

CRA4502 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. LBA3-LBA3 ◽  
Author(s):  
Karim Fizazi ◽  
Namphuong Tran ◽  
Luis Enrique Fein ◽  
Nobuaki Matsubara ◽  
Alfredo Rodríguez Antolín ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Randomized Trial ◽  
Abiraterone Acetate ◽  
Phase Iii ◽  
Newly Diagnosed ◽  
Double Blind ◽  
Daily News ◽  
Online Supplement ◽  
Final Text

LBA3 The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Saturday, June 3, 2017, and in the Annual Meeting Proceedings online supplement to the June 20, 2017, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. CRA9013-CRA9013
Author(s):  
Ellen M. Lavoie Smith ◽  
Herbert Pang ◽  
Constance Cirrincione ◽  
Stewart Barry Fleishman ◽  
Electra D. Paskett ◽  
...  
Keyword(s):  
Peripheral Neuropathy ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Phase Iii ◽  
Double Blind Trial ◽  
Double Blind ◽  
Daily News ◽  
Online Supplement ◽  
Blind Trial ◽  
Final Text

CRA9013 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. CRA3503-CRA3503 ◽  
Author(s):  
Dirk Arnold ◽  
Thierry Andre ◽  
Jaafar Bennouna ◽  
Javier Sastre ◽  
Pia J. Osterlund ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Phase Iii ◽  
Daily News ◽  
Online Supplement ◽  
Previously Treated ◽  
Final Text

CRA3503 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA5002-LBA5002 ◽  
Author(s):  
Eric Pujade-Lauraine ◽  
Felix Hilpert ◽  
Béatrice Weber ◽  
Alexander Reuss ◽  
Andres Poveda ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Recurrent Ovarian Cancer ◽  
Phase Iii ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
Final Text

LBA5002^ The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-non-methylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA2000-LBA2000
Author(s):  
Ulrich Herrlinger ◽  
Niklas Schaefer ◽  
Joachim Peter Steinbach ◽  
Astrid Weyerbrock ◽  
Peter Hau ◽  
...  
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
Newly Diagnosed ◽  
Daily News ◽  
Online Supplement ◽  
First Results ◽  
Final Text

LBA2000 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Saturday, June, 1, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA8500-LBA8500 ◽  
Author(s):  
Axel Hauschild ◽  
Jean Jacques Grob ◽  
Lev V. Demidov ◽  
Thomas Jouary ◽  
Ralf Gutzmer ◽  
...  
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
Kinase Inhibitor ◽  
Multicenter Trial ◽  
Phase Iii ◽  
Open Label ◽  
Daily News ◽  
Online Supplement ◽  
Final Text

LBA8500^ The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA4003-LBA4003
Author(s):  
Thierry Conroy ◽  
Marie-Pierre Galais ◽  
Jean Luc Raoul ◽  
Olivier Bouche ◽  
Sophie Gourgou-Bourgade ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Randomized Trial ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Phase Iii ◽  
Definitive Chemoradiotherapy ◽  
Daily News ◽  
Online Supplement ◽  
Final Text

LBA4003 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

Sign in / Sign up

Export Citation Format

Share Document